
New Cancer Pill Stops Pancreatic Tumours From Growing In 90% Of Patients
What Happened?
A new drug, daraxonrasib, has shown promising results in halting pancreatic tumours in 90% of patients. While not a cure, it may extend survival for those with advanced cancer.
Key points
- Daraxonrasib was tested on 61 patients with advanced pancreatic cancer.
- 90% of patients had their tumours stop growing.
- 60% experienced tumour shrinkage or disappearance.
- 76.6% of patients were alive one year after treatment.
- The drug is a KRAS inhibitor targeting specific gene mutations.
Key insights
- The drug's effectiveness may lead to longer survival rates for pancreatic cancer patients.
- If successful in further trials, daraxonrasib could change treatment protocols for various cancers.
- The results highlight a significant advancement in a field with historically low survival rates.
Why it matters
This development could provide hope for patients with limited treatment options for advanced pancreatic cancer.
Source
Times Now

